Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

The Anatomy of Recurrent Thrombosis and Its Risk Factors in Myeloproliferative Neoplasms

Silvia Betti, MD, Daniela Barraco, MD, Mythri Mudireddy, MBBS, Curtis A. Hanson, MD, Rhett P. Ketterling, MD, Animesh D. Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2017) 130 (Supplement 1): 4190.

https://doi.org/10.1182/blood.V130.Suppl_1.4190.4190

Published: 2017

Journal Articles

Phenotypic and Prognostic Relevance of the Who Diagnostic Distinction between Polycythemia Vera and JAK2 -Mutated Essential Thrombocythemia: Combined Analysis of 785 Informative Cases

Silvia Betti, MD, Daniela Barraco, MD, Mythri Mudireddy, MBBS, Curtis A. Hanson, MD, Rhett P. Ketterling, MD, Animesh D. Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2017) 130 (Supplement 1): 1645.

https://doi.org/10.1182/blood.V130.Suppl_1.1645.1645

Published: 2017

Journal Articles

Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series

Jennifer Yui, MD, Mythri Mudireddy, MBBS, Mrinal M Patnaik, MBBS, Naseema Gangat, MBBS, Aref Al-Kali, MD, Michelle Elliott, MD, William J. Hogan, MBChB, C. Christopher Hook, MD, Alexandra P Wolanskyj, MD, Mark R. Litzow, MD, Matthew T Howard, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, MD, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Kebede H. Begna, MD

Blood (2016) 128 (22): 2798.

https://doi.org/10.1182/blood.V128.22.2798.2798

Published: 2016

Journal Articles

Telomere Length In Granulocyte, Mononuclear, CD34 and CD3 Cell Fractions In Primary Myelofibrosis and Age Matched Controls

Rebecca R Laborde, PhD, Terra L Lasho, MT, (ASCP), Steven A Zincke, Christy Finke, BS, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 4069.

https://doi.org/10.1182/blood.V122.21.4069.4069

Published: 2013

Journal Articles

Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies

Meera Sridharan, MD, PhD, Aref Al-Kali, MD, Aneel A. Ashrani, MBBS, MSc, Kebede Begna, MD, Michelle Elliott, William J. Hogan, MBChB, Carl C. Hook, MD, Scott H. Kaufmann, MD, PhD, Louis Letendre, MD, Mark R. Litzow, MD, Mrinal M. Patnaik, MBBS, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Alexandra Wolanskyj, MD, Rajiv K. Pruthi, MBBS

Blood (2013) 122 (21): 5000.

https://doi.org/10.1182/blood.V122.21.5000.5000

Published: 2013

Journal Articles

Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis

Animesh D. Pardanani, MBBS, PhD, Terra L Lasho, MT(ASCP), Christy Finke, BS, Ramy A. Abdelrahman, MBBCh, Curtis A. Hanson, MD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 2824.

https://doi.org/10.1182/blood.V122.21.2824.2824

Published: 2013

Journal Articles

TP53 mutations and Polymorphisms in Primary Myelofibrosis,

Sania S Raza, MD, David Viswanatha, MD, Lori A Erickson, MD, Terra L Lasho, MT(ASCP), Christy Finke, BS, Ryan A Knudson, Rhett Ketterling, MD, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 3840.

https://doi.org/10.1182/blood.V118.21.3840.3840

Published: 2011

Journal Articles

JAK2 Haplotype SNP Analysis in Essential Thrombocythemia: Clinical and JAK2 V617F Allele Burden Correlates in 226 Patients.

Animesh D. Pardanani, MBBS, PhD, Terra Lasho, Christy Finke, BS, Kebede Hussein, MD, Michelle Elliott, MB, BCh, Ayalew Tefferi, MD

Blood (2009) 114 (22): 2893.

https://doi.org/10.1182/blood.V114.22.2893.2893

Published: 2009

Journal Articles

A JAK2 Germline Genetic Variation Is Associated with Shortened Survival in Primary Myelofibrosis: Clinical and JAK2V617F Allele Burden Correlates of rs12343867 SNP Genotype in 132 Cases.

Ayalew Tefferi, MD, Terra Lasho, Christy Finke, BS, Kebede Hussein, MD, Michelle Elliott, MB, BCh, Animesh D. Pardanani, MBBS, PhD

Blood (2009) 114 (22): 2895.

https://doi.org/10.1182/blood.V114.22.2895.2895

Published: 2009

Journal Articles

Indolent Mastocytosis in 159 Adults: Smoldering but Not Bone Marrow Only Variant Is Prognostically Significant.

Animesh D. Pardanani, MBBS, PhD, Ken-Hong Lim, MD, Terra L Lasho, MT(ASCP), Christy Finke, BS, Rebecca McClure, MD, Chin Yang Li, MD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 2906.

https://doi.org/10.1182/blood.V114.22.2906.2906

Published: 2009

Journal Articles

IPSS-Independent Cytogenetic Risk Categorization in Primary Myelofibrosis.

Kebede Hussein, MD, Animesh D. Pardanani, MBBS, PhD, Daniel van Dyke, Curtis A. Hanson, MD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 2909.

https://doi.org/10.1182/blood.V114.22.2909.2909

Published: 2009

Journal Articles

Long-Term Survival Data in 652 Patients with Primary Myelofibrosis or Polycythemia Vera— Trends in Recent Years.

Rakhee Vaidya, Naseema Gangat, MD, Sergio Siragusa, MD, Susan Schwager, Curtis A. Hanson, MD, Michelle Elliott, MB, BCh, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 2910.

https://doi.org/10.1182/blood.V114.22.2910.2910

Published: 2009

Journal Articles

Phase 1/2 Dose Finding Study of Pomalidomide in Myelofibrosis.

Ruben A. Mesa, MD, Animesh D. Pardanani, MBBS, PhD, Kebede Hussein, MD, Wenting Wu, PhD, Susan Schwager, Mark R. Litzow, MD, William J Hogan, MD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 2911.

https://doi.org/10.1182/blood.V114.22.2911.2911

Published: 2009

Journal Articles

Hypereosinophilia in 357 Consecutive Patients: Disease Spectrum and Clinical and Laboratory Correlates.

Ken-Hong Lim, MD, Ayalew Tefferi, MD, Chin Yang Li, MD, Animesh D. Pardanani, MBBS, PhD

Blood (2009) 114 (22): 3903.

https://doi.org/10.1182/blood.V114.22.3903.3903

Published: 2009

Journal Articles

Thrombotic Events in Primary Myelofibrosis: Prevalence and Prognostic Factors in 207 Consecutive Patients.

Michelle Elliott, MB, BCh, Terra Lasho, Christy Finke, BS, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 3915.

https://doi.org/10.1182/blood.V114.22.3915.3915

Published: 2009

Journal Articles

Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for Measuring Symptomatic Improvement: Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial.

Ruben A. Mesa, MD, Hagop Kantarjian, Ayalew Tefferi, MD, Richard Levy, MD, Kris Vaddi, Susan Erickson-Viitanen, PhD, Deborah A. Thomas, MD, Jorge Cortes-Franco, MD, Gautam Borthakur, MBBS, Animesh D. Pardanani, MBBS, PhD, Zeev Estrov, MD, Srdan Verstovsek, MD, PhD

Blood (2009) 114 (22): 3917.

https://doi.org/10.1182/blood.V114.22.3917.3917

Published: 2009

Journal Articles

Weight Loss, Splenomegaly, and Hypocholesterolemia in Myeloproliferative Neoplasms: Patterns and Relevance from the Pre JAK2 Inhibitor Era.

Ruben A. Mesa, MD, Susan Schwager, Jocelin Huang, MD, Animesh D. Pardanani, MBBS, PhD, Kebede Hussein, MD, John Camoriano, MD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 3918.

https://doi.org/10.1182/blood.V114.22.3918.3918

Published: 2009

Journal Articles

Long-Term Follow up and Optimized Dosing Regimen of INCB018424 in Patients with Myelofibrosis: Durable Clinical, Functional and Symptomatic Responses with Improved Hematological Safety.

Srdan Verstovsek, MD, PhD, Hagop Kantarjian, MD, Ruben A. Mesa, MD, Jorge Cortes-Franco, MD, Animesh D. Pardanani, MBBS, PhD, Deborah A. Thomas, MD, Zeev Estrov, MD, Edward C Bradley, MD, Susan Erickson-Viitanen, PhD, Kris Vaddi, Ph.D., Richard Levy, MD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 756.

https://doi.org/10.1182/blood.V114.22.756.756

Published: 2009

Journal Articles

A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2 V617F Allele Burden.

Animesh D. Pardanani, MBBS, PhD, Jason R Gotlib, MD, MS, Catriona Jamieson, MD, PhD, Jorge Cortes, MD, Moshe Talpaz, MD, Richard Stone, MD, Michael H Silverman, MD, FACP, Jolene Shorr, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 755.

https://doi.org/10.1182/blood.V114.22.755.755

Published: 2009

Journal Articles

Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with JAK2 and TET2 Mutational Status.

Ayalew Tefferi, MD, Sergio Siragusa, MD, Rakhee Vaidya, Susan Schwager, Kebede Hussein, MD, Curtis A. Hanson, MD, Animesh D. Pardanani, MBBS, PhD, Francisco Cervantes, Francesco Passamonti

Blood (2009) 114 (22): 1909.

https://doi.org/10.1182/blood.V114.22.1909.1909

Published: 2009

NARROW

The Anatomy of Recurrent Thrombosis and Its Risk Factors in Myeloproliferative Neoplasms

Phenotypic and Prognostic Relevance of the Who Diagnostic Distinction between Polycythemia Vera and JAK2 -Mutated Essential Thrombocythemia: Combined Analysis of 785 Informative Cases

Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series

Telomere Length In Granulocyte, Mononuclear, CD34 and CD3 Cell Fractions In Primary Myelofibrosis and Age Matched Controls

Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies

Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis

TP53 mutations and Polymorphisms in Primary Myelofibrosis,

JAK2 Haplotype SNP Analysis in Essential Thrombocythemia: Clinical and JAK2 V617F Allele Burden Correlates in 226 Patients.

A JAK2 Germline Genetic Variation Is Associated with Shortened Survival in Primary Myelofibrosis: Clinical and JAK2V617F Allele Burden Correlates of rs12343867 SNP Genotype in 132 Cases.

Indolent Mastocytosis in 159 Adults: Smoldering but Not Bone Marrow Only Variant Is Prognostically Significant.

IPSS-Independent Cytogenetic Risk Categorization in Primary Myelofibrosis.

Long-Term Survival Data in 652 Patients with Primary Myelofibrosis or Polycythemia Vera— Trends in Recent Years.

Phase 1/2 Dose Finding Study of Pomalidomide in Myelofibrosis.

Hypereosinophilia in 357 Consecutive Patients: Disease Spectrum and Clinical and Laboratory Correlates.

Thrombotic Events in Primary Myelofibrosis: Prevalence and Prognostic Factors in 207 Consecutive Patients.

Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for Measuring Symptomatic Improvement: Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial.

Weight Loss, Splenomegaly, and Hypocholesterolemia in Myeloproliferative Neoplasms: Patterns and Relevance from the Pre JAK2 Inhibitor Era.

Long-Term Follow up and Optimized Dosing Regimen of INCB018424 in Patients with Myelofibrosis: Durable Clinical, Functional and Symptomatic Responses with Improved Hematological Safety.

A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2 V617F Allele Burden.

Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with JAK2 and TET2 Mutational Status.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only